Abstract:Cyclin-dependent kinases (CDKs), particularly CDK4 and CDK2, are crucial for cell cycle progression from the Gap 1 (G1) to the Synthesis (S) phase by phosphorylating targets such as the Retinoblastoma Protein (Rb). CDK4, paired with cyclin-D, operates in the long G1 phase, while CDK2 with cyclin-E, manages the brief G1-to-S transition, enabling DNA replication. Aberrant CDK signaling leads to uncontrolled cell proliferation, which is a hallmark of cancer. Exactly how they accomplish their catalytic phosphorylation actions with distinct efficiencies poses the fundamental, albeit overlooked question. Here we combined available experimental data and modeling of the active complexes to establish their conformational functional landscapes to explain how the two cyclin/CDK complexes differentially populate their catalytically competent states for cell cycle progression. Our premise is that CDK catalytic efficiencies could be more important for cell cycle progression than the cyclin-CDK biochemical binding specificity and that efficiency is likely the prime determinant of cell cycle progression. We observe that CDK4 is more dynamic than CDK2 in the ATP binding site, the regulatory spine, and the interaction with its cyclin partner. The N-terminus of cyclin-D acts as an allosteric regulator of the activation loop and the ATP-binding site in CDK4. Integrated with a suite of experimental data, we suggest that the CDK4 complex is less capable of remaining in the active catalytically competent conformation, and may have a lower catalytic efficiency than CDK2, befitting their cell cycle time scales, and point to critical residues and motifs that drive their differences. Our mechanistic landscape may apply broadly to kinases, and we propose two drug design strategies: (i) allosteric Inhibition by conformational stabilization for targeting allosteric CDK4 regulation by cyclin-D, and (ii) dynamic entropy-optimized targeting which leverages the dynamic, entropic aspects of CDK4 to optimize drug binding efficacy.

Cdk5 May Be an Atypical Kinase, but Not in the Way You Think

Cdk5 and the non-catalytic arrest of the neuronal cell cycle.

Nucleocytoplasmic Cdk5 Is Involved In Neuronal Cell Cycle And Death In Post-Mitotic Neurons

Cyclin Dependent Kinase 5 and Its Interacting Proteins in Cell Death Induced in Vivo by Cyclophosphamide in Developing Mouse Embryos

Cdk5 Suppresses The Neuronal Cell Cycle By Disrupting The E2f1-Dp1 Complex

Nuclear Localization Of Cdk5 Is A Key Determinant In The Postmitotic State Of Neurons

Cyclin-Dependent Kinase 5--A Neuronal Killer?

Cdk5 Levels Oscillate during the Neuronal Cell Cycle: Cdh1 UBIQUITINATION TRIGGERS PROTEOSOME-DEPENDENT DEGRADATION DURING S-PHASE

Why minimal is not optimal: Driving the mammalian cell cycle—and drug discovery—with a physiologic CDK control network

P1‐285: Nucleocytoplasmic Cdk5 Links Cell Cycle and Cell Death in Post‐mitotic Neurons in Alzheimer's Disease

CDK5-cyclin B1 regulates mitotic fidelity

When Good Cdk5 Turns Bad

The Role of Cdk5 in Neurological Disorders

Proteomic Analysis of the Human Cyclin-dependent Kinase Family Reveals a Novel CDK5 Complex Involved in Cell Growth and Migration

Neuroprotective Mechanisms Mediated by CDK5 Inhibition.

CK1δ Activity is Modulated by CDK2/E- and CDK5/p35-mediated Phosphorylation

CDK2 and CDK4: Cell Cycle Functions Evolve Distinct, Catalysis-Competent Conformations, Offering Drug Targets

Cell type-specific expression, regulation and compensation of CDKL5 activity in mouse brain

Cdk5-mediated inhibition of APC/C-Cdh1 switches on the cyclin D1-Cdk4-pRb pathway causing aberrant S-phase entry of postmitotic neurons

Discovery and characterization of a specific inhibitor of serine-threonine kinase cyclin-dependent kinase-like 5 (CDKL5) demonstrates role in hippocampal CA1 physiology

Cyclin-Dependent Kinase 5 Is Associated With Apoptotic Cell Death During Development And Tissue Remodeling